Phaseline

Targets › CD123

CD123: drug programs, companies and trials

11 programs from 10 companies in 11 trials: 11 Phase 1; Oncology; next expected readout Nov 2026.

Open in Phaseline: the race on CD123, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
MacroGenicsMGD024
CD123 x CD3 bispecific DART molecule
CD123, CD3Phase 1Leukemia, Acute MyeloidNov 2026
Essen BiotechCD123/CD33 CAR-T (EB-BH2025)
CAR-T cells targeting CD123 and/or CD33 sequentially
CD123, CD33Phase 1AMLDec 2026
Xuzhou Medical Universityanti Tim-3/CD123 CAR-T cell therapy
Dual-targeted CAR-T cell therapy targeting Tim-3 and CD123
HAVCR2, CD123Phase 1Acute Myeloid Leukemia RefractoryJan 2027
AvenCell EuropeAllo-RevCAR01-T-CD123
Allogeneic multi-edited CAR-T cells with reversed CAR (RevCAR) bridged to CD123 via R-TM12
CD123Phase 1Acute Myeloid Leukemia, in RelapseMay 2027
Chongqing Precision BiotechAnti-CD123 CAR NK cells
anti-CD123 CAR-NK cells
CD123Phase 1AML (Acute Myeloid Leukemia)Jun 2027
City of Hope Medical CenterAllogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes
CD123-targeted allogeneic CAR-T cell therapy with CD28 costimulatory domain
CD123Phase 1Adult Acute Myeloid Leukemia in RemissionJul 2027
City of Hope Medical CenterAutologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes
CD123-targeted CAR-T cell therapy with CD28 costimulatory domain
CD123Phase 1Adult Acute Myeloid Leukemia in RemissionJul 2027
University of PennsylvaniaCART123 Cells
CAR-T cell therapy targeting CD123-expressing cells
CD123Phase 1Relapsed AMLMar 2045
Chunji GaoDonor-derived CD123-CD16 bispecific antibody-modified NK cells
CD123-CD16 bispecific antibody-modified NK cells for AML targeting
CD123, FCGR3APhase 1AML (Acute Myelogenous Leukemia)–
Gilead SciencesSPRX002
Soluble protein antigen-receptor X-linker with CD123-targeting binding region; serves as b
CD123Phase 1Acute Myeloid Leukemia–
CellectisUCART123v1.2
Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor
CD123Phase 1Relapsed/Refractory Acute Myeloid Leukemia–

Conditions

Adult Acute Myeloid Leukemia in Remission (2) AML (Acute Myeloid Leukemia) (1) Relapsed/Refractory Acute Myeloid Leukemia (1) AML (Acute Myelogenous Leukemia) (1) Relapsed AML (1) Acute Myeloid Leukemia (1) Acute Myeloid Leukemia, in Relapse (1) AML (1) Acute Myeloid Leukemia Refractory (1) Leukemia, Acute Myeloid (1)

Modalities

other (4), mixed (4), small molecule (2), protein or peptide (1)

Companies

City of Hope Medical Center (2) Chongqing Precision Biotech (1) Cellectis (1) Chunji Gao (1) University of Pennsylvania (1) Gilead Sciences (1) AvenCell Europe (1) Essen Biotech (1) Xuzhou Medical University (1) MacroGenics (1)

Related targets

FCGR3A (1) CD33 (1) HAVCR2 (1) CD3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.